Long-term results from a major U.S. federal study ease worries about the safety of a hormone-blocking drug that can lower a man's chances of developing prostate cancer. The drug cut prostate cancer risk by 30 per cent without raising the risk of dying of an aggressive form of the disease as earlier results hinted it might.
A new study raises a red flag about a therapy commonly used in advanced prostate cancer. The work suggests that what's known as androgen deprivation therapy may increase a patient's risk of developing acute kidney injury.
A new study is raising questions about omega-3 fatty acids, which are found in oily fish and fish supplements, suggesting that men with high levels of the oils in their bloods might also have a higher risk of prostate cancer.
According to Prostate Cancer Canada, there is no single cause of prostate cancer, but there are several risk factors. It’s important for men to keep in mind that it is possible to develop prostate cancer even when none of the factors are present. Early detection is important.
Men with low-risk, slow-growing prostate cancer are often advised to skip surgery or radiation in favour of “watchful waiting.” But there could soon be another option: an ultrasound technique that’s being pioneered by Canadians.
A new study shows how important it is for men to carefully consider treatments for early-stage prostate cancer. Fifteen years after surgery or radiation treatment, nearly all of the older men in the study had some problems having sex.
The PSA screening test: does it save lives, or does it do more harm than good?
It’s one of the most contentious questions asked of family doctors and oncologists. And, for the moment, it seems like the answer is: it depends.
Six months after issuing a preliminary draft recommendation against PSA prostate cancer screening, the U.S. Preventive Services Task Force has recently finalized its position: It now formally recommends AGAINST screening.